The
The measure, which still needs to be approved by the
"Emerging evidence suggests that a second booster dose of an mRNA COVID-19 vaccine improves protection against severe COVID-19 and is not associated with new safety concerns," the FDA said in a statement.
The FDA said the second booster of the vaccine may be administered at least four months after receipt of a first booster. The agency added that a second booster dose can be given to individuals 12 years of age and older who are immunocompromised.
"Based on an analysis of emerging data, a second booster dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine could help increase protection levels for these higher-risk individuals," Dr.
"Additionally, the data show that an initial booster dose is critical in helping to protect all adults from the potentially severe outcomes of COVID-19. So, those who have not received their initial booster dose are strongly encouraged to do so."
The FDA said it will continue to evaluate data and information as it becomes available on the potential use of a second booster dose in other age groups.
Copyright 2022 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source